EcoDrugPlus

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSOKIG00005015279
Gene Symbol: LOC109901482
2 Cross references
331 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSOKIG00005013907
Gene Symbol: LOC109902124
2 Cross references
300 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSOKIG00005013904
Gene Symbol: LOC109903807
2 Cross references
332 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSOKIG00005018848
Gene Symbol: LOC109906938
3 Cross references
320 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSOKIG00005012555
Gene Symbol: FRK
3 Cross references
156 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSOKIG00005005555
Gene Symbol: FRK
3 Cross references
156 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSOKIG00005029623
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin 3

Ensembl ID : ENSOKIG00005050331
Gene Symbol: LGALS3
3 Cross references
160 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1

Ensembl ID : ENSOKIG00005030557
Gene Symbol: LOC109872851
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSOKIG00005049341
Gene Symbol: LOC109892967
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6

Ensembl ID : ENSOKIG00005034531
Gene Symbol: LOC109865062
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-6-Like

Ensembl ID : ENSOKIG00005004238
Gene Symbol: LOC109905979
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).